Brokerages Set Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Price Target at $16.56

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report) have earned a consensus rating of “Buy” from the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $16.5556.

Several equities analysts have issued reports on IVA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Wall Street Zen cut shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Truist Financial began coverage on shares of Inventiva in a research note on Thursday, March 19th. They set a “buy” rating and a $13.00 price target on the stock.

Get Inventiva alerts:

Check Out Our Latest Report on IVA

Hedge Funds Weigh In On Inventiva

Institutional investors and hedge funds have recently made changes to their positions in the stock. Creative Planning acquired a new position in shares of Inventiva during the 2nd quarter worth $32,000. Virtu Financial LLC acquired a new position in shares of Inventiva during the 4th quarter worth $60,000. XTX Topco Ltd acquired a new position in shares of Inventiva during the 4th quarter worth $84,000. Cerity Partners LLC acquired a new position in shares of Inventiva during the 4th quarter worth $93,000. Finally, NewEdge Advisors LLC acquired a new position in shares of Inventiva during the 3rd quarter worth $116,000. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Price Performance

Shares of IVA opened at $4.23 on Friday. The company’s fifty day moving average is $5.29 and its two-hundred day moving average is $5.41. Inventiva has a 1 year low of $2.85 and a 1 year high of $7.98.

Inventiva (NASDAQ:IVA – Get Free Report) last announced its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million for the quarter. On average, sell-side analysts predict that Inventiva will post -0.8 earnings per share for the current year.

Inventiva Company Profile

(Get Free Report)

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.

Featured Stories

• Five stocks we like better than Inventiva
• The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
• Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
• Medtronic Bottoms, Healthy Rebound Ahead
• GitLab’s Price Recovery Gains Traction—Time to Get On Board?

Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.